M

Madrigal Pharmaceuticals
D

MDGL

370.00
USD
-1.42
(-0.38%)
مغلق
حجم التداول
22,539
الربح لكل سهم
-12
العائد الربحي
-
P/E
-28
حجم السوق
8,246,935,180
أصول ذات صلة
EXEL
EXEL
-0.195
(-0.51%)
38.310 USD
INSM
INSM
0.100
(0.08%)
127.870 USD
K
KPTI
1.23600
(26.22%)
5.95000 USD
المزيد
الأخبار المقالات

العنوان: Madrigal Pharmaceuticals

القطاع: Healthcare
الصناعة: Biotechnology
Madrigal Pharmaceuticals Inc is a biopharmaceutical company focused on delivering novel therapeutics for metabolic dysfunction-associated steatohepatitis (MASH), a serious liver disease with high unmet medical need that can lead to cirrhosis, liver failure, and premature mortality. The company's medication, Rezdiffra (resmetirom), is a once-daily, oral, liver-directed thyroid hormone receptor agonist designed to target key underlying causes of MASH.